Telix Beyond TLX591: A Mid-Term Long on a Commercializing Radiopharma Platform
Telix (TLX) is trading near $7.25 with a $2.45B market cap. Recent commercial approvals, a 56% revenue uptick in 2025 and an owned radiopharmacy network position the company to scale imaging and therapeutic sales even if TLX591-Tx is delayed or stumbles. This trade targets a rebound to $10.00 over a mid-term window while limiting downside to $6.25.